4D Molecular Therapeutics (FDMT) Shares Outstanding (Diluted Average) (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $68.1 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $68.1 million, up 22.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $68.1 million (up 22.1% YoY), and the FY2025 annual result was $57.9 million, up 7.39% from the prior year.
• Shares Outstanding (Diluted Average) rose to $68.1 million in Q1 2026 per FDMT's latest filing, from $57.9 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $68.1 million in Q1 2026 and troughed at $32.2 million in Q1 2022.
• A 5-year average of $46.2 million and a median of $49.3 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Diluted Average) jumped 50.57% in 2024, then increased 0.68% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $32.4 million in 2022, then increased by 20.95% to $39.1 million in 2023, then soared by 37.86% to $53.9 million in 2024, then climbed by 7.39% to $57.9 million in 2025, then climbed by 17.49% to $68.1 million in 2026.
• Business Quant data shows FDMT's Shares Outstanding (Diluted Average) at $68.1 million in Q1 2026, $57.9 million in Q4 2025, and $55.9 million in Q3 2025.